Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ARCT-154

Vaccine (mRNA vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Arcturus Therapeutics

Phase 2/3 Most advanced trial (none active)
ARCT Developer
2 Registered trials

What is ARCT-154?

ARCT-154 is a self-amplifying RNA vaccine against SARS-CoV-2, the virus that causes COVID-19. It is studied for prevention of COVID-19 and SARS-CoV-2 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (mRNA vaccine)
Targets
SARS-CoV-2 spike protein (antigen)
Mechanism
Immune activation, directed at SARS-CoV-2 spike protein
Therapy area
Infectious disease
Developer
Arcturus Therapeutics, Inc. (ARCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05012943 Phase 2/3 COVID-19 Vaccines Completed ARCT
NCT05037097 Phase 1/2 COVID-19 Completed ARCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Corona Virus InfectionCOVID-19COVID-19 VaccinesSARS-CoV-2 Infection

More from Arcturus Therapeutics

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARCT page.

Follow ARCT, the company behind ARCT-154

See ARCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.